CLINICAL_TRIALS
trial_result
· 2007-08-03
Clinical Trial Update: Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia [Phase 2]
Summary
A Phase 2 clinical trial evaluating STI571 (imatinib) for Philadelphia chromosome–positive chronic myeloid leukemia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Bologna | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED